Valneva: MA application deemed acceptable by EMA

(CercleFinance.com) - Valneva has announced that the European Medicines Agency (EMA) has accepted its marketing authorisation application (MAA) for its single-dose chikungunya vaccine candidate VLA1553.


The chikungunya virus, or CHIKV, has already spread to over 110 countries, and the risk of chikungunya spreading to Europe is relatively high due to the possibility of infected travellers, Valneva said.

VLA1553 was approved by the US FDA at the beginning of November under the brand name Ixchiq. In mid-November, Valneva also announced positive results from a pivotal phase III study in adolescents on the immunogenicity of the product.



Copyright (c) 2023 CercleFinance.com. All rights reserved.